Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates

Vaccine

Volumn 16, Issue 8, 1998, Pages 842-849

  Konishi, Eiji ^a   Kurane, Ichiro ^b,c   Mason, Peter W ^d   Shope, Robert E ^e,f   Kanesa Thasan, Niranjan ^g   Smucny, John J ^g   Hoke Jr , Charles H ^g   Ennis, Francis A ^b  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f University of Texas Medical Branch School of Medicine   (United States)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Cytotoxic T lymphocytes; Japanese encephalitis; Recombinant vaccine

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; RECOMBINANT VACCINE; VIRUS PROTEIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; JAPANESE ENCEPHALITIS VIRUS; MALE; MONONUCLEAR CELL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS ENCEPHALITIS;

EID: 0032078773     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00265-X     Document Type: Article

References (39)

1. 1 Shope, R.E. Medical significance of togaviruses: an overview of diseases caused by togaviruses in man and in domestic and wild vertebrate animals. In: The Togaviruses (Ed. Schfesinger, R.W.) Academic Press, New York, 1980, pp. 47-82
2. 2 Monath, T.P. Pathobiology of the flaviviruses. In: The Togaviridae and Flaviviridae (Eds Schlesinger, S. and Schlesinger, M.J.) Plenum Press, New York/London, 1986, pp. 375-440
3. 3 Brandt, W.E. Current approaches to the development of dengue vaccines and related aspects of the molecular biology of flaviviruses. Journal of Infectious Diseases 1988, 157, 1105-1111.
4. 4 Byrne, J.A. and Oldstone, M.B.A Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. Journal of Virology 1984, 51, 682-686.
5. 5 Kuwano, K., Scott, M., Young, J.F. and Ennis, F.A. HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response, Journal of Immunology 1988, 140, 1264-1268.
6. 6 Kimura-Kuroda, J. and Yasui, K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. Journal of Immunology 1988, 141, 3606-3610.
7. 7 Mason, P.W., Dalrymple, J.M. and Gentry, M.K. et al. Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. Journal of General Virology 1989, 70, 2037-2049.
8. 8 Mathur, A., Arora, K.L. and Chaturvedi, U.C. Host defense mechanisms against Japanese encephalitis virus infection in mice. Journal of General Virology 1983, 64, 805-811.
9. 9 Miura, K., Onodera, T., Nishida, A., Goto, N. and Fujisaki, Y. A single gene controls resistance to Japanese encephalitis virus in mice. Archives of Virology 1990, 112, 261-270.
10. 10 Murali-Krishna, K., Ravi, V. and Manjunath, R. Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells. Journal of General Virology 1996, 77, 705-714.
11. + cytotoxic T lymphocytes in mice. Virology 1997, 227, 353-360.
12. 12 Venugopal, K. and Gould, E.A. Towards a new generation of flavivirus vaccines. Vaccine 1994, 12, 966-975.
13. 13 Germain, R.N. Antigen processing and presentation. In: Fundamental Immunology (Ed. Paul, W.E.), 3rd edn. Raven Press, New York, 1993, pp. 629-676
14. 14 Konishi, E., Pincus, S. and Paoletti, E. et al. A highly attenuated host-range-restricted vaccinia virus strain, NYVAC, encoding the prM, E and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 1992, 190, 454-458.
15. 15 Konishi, E., Pincus, S., Paoletti, E., Shope, R.E. and Mason, P.W. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine 1994, 12, 633-638.
16. 16 Tartaglia, J., Perkus, M.E. and Taylor, J. et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992, 188, 217-232.
17. 17 Mason, P.W. Maturation of Japanese encephalitis virus glyco-proteins produced by infected mammalian and mosquito cells. Virology 1989, 169, 354-364.
18. 18 Mason, P.W., Pincus, S. and Fournier, M.J. et al. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 1991, 180, 294-305.
19. 19 Kurane, I., Innis, B.L. and Nisalak, A. et al. Human T cell responses to dengue virus antigens: proliferative responses and interferon gamma production. Journal of Clinical Investigation 1989, 83, 506-513.
20. 20 Konishi, E., Pincus, S. and Fonseca, B.A.L. et al. Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology 1991, 185, 401-410.
21. 21 Konishi, E., Kurane, I., Mason, P.W., Innis, B.L. and Ennis, F.A. Japanese encephalitis virus-specific proliferative responses of human peripheral blood T lymphocytes. American Journal of Tropical Medicine and Hygiene 1995, 53, 278-283.
22. + T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination. J. Virol. 1993, 67, 5962-5967.
23. + CD8 cytotoxic T-cell clones. Journal of Virology 1994, 68, 3283-3288.
24. 24 Rooney, J.F., Wohlenberg, C., Cremer, K.J., Moss, B. and Notkins, A.L. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. Journal of Virology 1988, 62, 1530-1534.
25. 25 Johnson, M.P., Meitin, C.A., Bender, B.S. and Small, P.A. Jr. Passive immune serum inhibits antibody response to recombinant vaccinia virus. In: Vaccines 88 (Eds Ginsberg, H., Brown, F., Lerner, R.A. and Chanock, R.M.) Cold Spring Harbor Laboratory, New York, 1988, pp. 189-192
26. 26 Cooney, E.L., Collier, A.C. and Greenberg, P.D. et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991, 337, 567-572.
27. + cytotoxic T lymphocytes in humans. Journal of Virology 1993, 67, 1538-1544.
28. + cytotoxic T-lymphocyte clones. Journal of Virology 1992, 66, 2274-2280.
29. 29 Pialoux, G., Excler, J.L. and Riviere, Y. et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Research and Human Retroviruses 1995, 11, 373-381.
30. 30 Egan, M.A., Pavlat, W.A. and Tartaglia, J. et al. Induction of human immunodeficiency vtrus type 1 (HIV-1)-specific cytotoxic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. Journal of Infectious Diseases 1995, 171, 1623-1627.
31. 31 Fleury, B., Janvier, G. and Pialoux, G. et al. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1 )-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. Journal of Infectious Diseases 1996, 174, 734-738.
32. 32 Perales, M.A., Schwartz, D.H., Fabry, J.A. and Lieberman, J. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1995, 10, 27-35.
33. 33 Borysiewicz, L.K., Fiander, A. and Nimako, M. et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347, 1523-1527.
34. 34 Cadoz, M., Strady, A. and Meignier, B. et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992, 339, 1429-1432.
35. 35 Donnelly, J.J., Ulmer, J.B. and Liu, M.A. Immunization with DNA. Journal of Immunological Methods 1994, 176, 145-152.
36. 36 Jones, P.D., Tha-Hla, R., Morein, B., Lovgren, K. and Ada, G.L. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms). Scandinavian Journal of Immunology 1988, 27, 645-652.
37. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMS. Nature 1990, 344, 873-875.
38. 38 Reddy, R., Zhou, F., Nair, S., Huang, L. and Rouse, B.T. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. Journal of Immunology 1992, 148, 1585-1589.
39. 39 Layton, G.T., Harris, S.J. and Gearing, A.J. et al. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. Journal of Immunology 1993, 151, 1097-1107.